^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:Talvey (talquetamab-tgvs) (CD3 agonist, GPRC5D inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    J&J Press Release
    Title:

    European Commission Approves TALVEY®▼ (talquetamab), Janssen’s Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

    Published date:
    08/22/2023
    Excerpt:
    The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted conditional marketing authorization (CMA) of TALVEY (talquetamab) as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    08/10/2023
    Excerpt:
    TALVEY is a bispecific GPRC5D-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    08/25/2023
    Excerpt:
    Multiple Myeloma: THERAPY FOR PREVIOUSLY TREATED MULTIPLE MYELOMA...Talquetamab-tgvs…